Redcare Pharmacy NV
XETRA:RDC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
98
170.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RDC stock under the Base Case scenario is 119.81 EUR. Compared to the current market price of 144.9 EUR, Redcare Pharmacy NV is Overvalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Redcare Pharmacy NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RDC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Redcare Pharmacy NV
Balance Sheet Decomposition
Redcare Pharmacy NV
Current Assets | 516.1m |
Cash & Short-Term Investments | 209.9m |
Receivables | 104.7m |
Other Current Assets | 201.5m |
Non-Current Assets | 502.8m |
Long-Term Investments | 6.3m |
PP&E | 80.7m |
Intangibles | 414.2m |
Other Non-Current Assets | 1.7m |
Current Liabilities | 243.9m |
Accounts Payable | 181.2m |
Other Current Liabilities | 62.7m |
Non-Current Liabilities | 269.7m |
Long-Term Debt | 234.7m |
Other Non-Current Liabilities | 35m |
Earnings Waterfall
Redcare Pharmacy NV
Revenue
|
2.2B
EUR
|
Cost of Revenue
|
-1.7B
EUR
|
Gross Profit
|
516.7m
EUR
|
Operating Expenses
|
-533m
EUR
|
Operating Income
|
-16.4m
EUR
|
Other Expenses
|
-8.2m
EUR
|
Net Income
|
-24.6m
EUR
|
Free Cash Flow Analysis
Redcare Pharmacy NV
EUR | |
Free Cash Flow | EUR |
In Q3, sales surged by 34% to EUR 1.8 billion, with a remarkable eRx growth rate of 81%, now accelerating to 130% in October. The company recorded an adjusted EBITDA margin of 2%, impacted by increased marketing efforts, while year-to-date EBITDA stands at 2.3%. Non-Rx sales exceeded 20% growth, prompting a revised guidance for full-year sales to between EUR 2.35 billion and EUR 2.5 billion. Active customers grew to 12 million, reflecting sustained demand. The company aims to enhance market share in the addressable EUR 55 billion Rx market from the current 0.66%.
What is Earnings Call?
RDC Profitability Score
Profitability Due Diligence
Redcare Pharmacy NV's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Redcare Pharmacy NV's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
RDC Solvency Score
Solvency Due Diligence
Redcare Pharmacy NV's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Redcare Pharmacy NV's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RDC Price Targets Summary
Redcare Pharmacy NV
According to Wall Street analysts, the average 1-year price target for RDC is 160.72 EUR with a low forecast of 85.85 EUR and a high forecast of 212.1 EUR.
Dividends
Current shareholder yield for RDC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RDC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Redcare Pharmacy NV engages in the business of prescription and non-prescription pharmaceuticals; beauty and personal care (BPC) products; and food supplements. The company is headquartered in Sevenum, Limburg and currently employs 1,847 full-time employees. The company went IPO on 2016-10-13. The firm focuses on non-prescription medication (OTC), as well as on pharmacy-related beauty and personal care (BPC) products. The firm is active in Belgium, Spain, Italy, France, Austria, the Netherlands and Germany.
Contact
IPO
Employees
Officers
The intrinsic value of one RDC stock under the Base Case scenario is 119.81 EUR.
Compared to the current market price of 144.9 EUR, Redcare Pharmacy NV is Overvalued by 17%.